BHC - BHC Investors Should Contact Robbins LLP About Participating in the Class Action Against Bausch Health Companies Inc. | Benzinga
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Bausch Health Companies Inc. (NYSE:BHC) securities between August 6, 2020 and May 3, 2023. Bausch, the successor entity of Valeant Pharmaceuticals International, Inc., is a pharmaceutical company known for its majority ownership of Bausch + Lomb Corporation ("B+L").
For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is this Case About: Bausch Health Companies Inc. (BHC) Misled Investors Regarding the Benefits of its Spin Off of B+L to Avoid Paying Damages for Previous Fraudulent Activity
According to the complaint, in 2016, Bausch replaced its senior management and attempted to rebuild its reputation after it engaged in one of the most egregious cases of securities fraud in U.S. history, which resulted in a class action settlement of more than $1.1. billion to ...